bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

Phase 2

• Conditions: Cutaneous Warts
• Interventions: Drug: bLAC; Drug: Placebo

• Registration Number: NCT00644579
• Lead Sponsor: NatImmune A/S

Brief Summary

As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC in two dose groups to immune suppressed, kidney transplanted patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2008-03
• Study Start: 2008-03
• Study First Submitted: 2008-03-25
• Study First Submitted QC: 2008-03-26
• Last Update Submitted: 2008-03-26
• Study First Posted: 2008-03-27
• Last Update Posted: 2008-03-27
• Primary Completion: 2008-12
• Study Completion: 2009-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Cutaneous warts on ingers and/or palms and/or toes and/or soles of feet
• Common warts and mosaic warts, diagnosed by an experienced dermatologist
• Solitary wart lesions or 2 or more lesions per patient
• Lesions present for more than 6 months
• Men or women, aged 18 or above
• History of kidney transplantation and immune suppressive therapy after transplant
• Concomitant immune suppressive therapy stable for 6 months prior to randomization
• Agreement from patient to allow photographs to be taken and used as part of trial data documentation (2 centres)
• Women of childbearing potential must have negative pregnancy test at screening and must use adequate contraception
• Ability to comply with requirements of trial
• Written informed consent

Exclusion Criteria

• Verruca plana lesions
• Suspected allergy to milk verified by serum analysis of IgE towards cow milk
• Breastfeeding
• Any local medication for any purpose other than wart treatment in target area during 4 weeks prior to randomization and during treatment period
• Concomitant treatment with other wart therapies two weeks prior to randomization and during trial period
• Intolerance towards bovine alpha-lactalbumin, oleic acid or any excipient in the formulation
• Known HIV infection or any current uncontrolled infection
• Any chronic or acute skin condition susceptible of interfering with evaluation of drug effect in this trial
• Participation in any investigational trial or use of any investigational drug within 30 days prior to inclusion in this trial
• Any health problems which according to Investigator's clinical judgment will make the patient unsuitable for inclusion in the trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	bLAC	bLAC high dose
2	bLAC	bLAC low dose
3	Placebo	-

Primary Outcome Measures

Name	Time	Method
Reduction in the area of wart lesions located on fingers and/or palms and/or toes and/or soles of the feet, measured by an objective method by drawing of individual lesions	Prospective

Secondary Outcome Measures

Name	Time	Method
Clearance of index wart lesions. Time to clearance of warts. Recurrence rate of previously cleared wart lesions. Occurrence of new warts.overall changes of index warts lesions. Safety and tolerability.	Prospective

Trial Locations

Locations (5)

Marselisborg University Hospital; 🇩🇰 Aarhus C, Denmark

Bispebjerg University Hospital; 🇩🇰 Copenhagen NV, Denmark

Gentoftte Amtssygehus; 🇩🇰 Hellerup, Denmark

Odense University Hospital; 🇩🇰 Odense, Denmark

Dermatology Clinic, Vesterbro; 🇩🇰 Aalborg, Denmark